[go: up one dir, main page]

KR950700054A - 생물학적 물질의 코팅 또는 캡슐화 고분자 및 그 방법 - Google Patents

생물학적 물질의 코팅 또는 캡슐화 고분자 및 그 방법

Info

Publication number
KR950700054A
KR950700054A KR1019940703035A KR19940703035A KR950700054A KR 950700054 A KR950700054 A KR 950700054A KR 1019940703035 A KR1019940703035 A KR 1019940703035A KR 19940703035 A KR19940703035 A KR 19940703035A KR 950700054 A KR950700054 A KR 950700054A
Authority
KR
South Korea
Prior art keywords
biological material
macromer
free radical
encapsulating
cells
Prior art date
Application number
KR1019940703035A
Other languages
English (en)
Other versions
KR100323043B1 (ko
Inventor
제프리 에이. 후벨
챈드라세크하르 피. 페탁
아마프리트 에스. 소니
네일 피. 데사이
제니퍼 엘. 힐
시에드 에프. 에이. 호사이니
Original Assignee
레이 파라비
보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이 파라비, 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 레이 파라비
Publication of KR950700054A publication Critical patent/KR950700054A/ko
Application granted granted Critical
Publication of KR100323043B1 publication Critical patent/KR100323043B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
    • C08F290/06—Polymers provided for in subclass C08G
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
    • C08F290/06—Polymers provided for in subclass C08G
    • C08F290/062—Polyethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F291/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds according to more than one of the groups C08F251/00 - C08F289/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D153/00—Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/32—Polylysine, polyornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 생물학적 물질의 코팅 또는 캡슐화 고분자 및 그 방법으로서, 특히 수용성 머크로머가 카르본-탄소 이중 또는 삼중결합을 가진 자유라디칼 중합기의 첨가에 의해 수정되고, 상기 중합기는 섬유질, 세포 또는 생물학적으로 활동성 있는 물질을 캡슐화하기 위하여 평온한 조건하에서 중합될 수 있다. 상기 중합물질은 특히 섬유질 유착제, 혈관을 포함한 섬유상 루멘의 코팅제, 란게르한스섬과 같은 세포의 코팅제, 코티제, 플러그, 신체등의 생물학적 물질과 접촉하기 위한 보조제 또는 기질으로서 유용하며 생물학적 활동분자의 약제 전달 수단으로서도 유용하다.

Description

생물학적 물질의 코딩 또는 캡슐화 고분자 및 그 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 중합이 시작된 에틸에오신의 반응도, 제2도(가)는 가교화된 알긴산염 마이크로스피어 주위에 PEG층의 염료개시중합을 도시한 상태도, 제2도(나)는 제2(가)도에 설명된 염료결합방법을 사용하여 PEG 18.5K 테트라아크릴레이트(하이드로 겔로 코팅된 사람의 랑게르한스섬을 포함하는 아기네이트/폴리리신마이크로캡슐의 현미경 사진, 제3도는 광물성기름에 매달린 아기네이트/폴리리신마이크로캡슐위에 PEG 코팅의 광중합상태도, 제4도는 PEG 18.5K 4가 테트라아크릴레이트 하이드로겔에 캡슐화한 인간의 췌장으로 부터 분리된 링게르한스섬의 현미경 사진, 제5도는 레이져 중합을 이용한 마이크로캡슐에 사용되는 동시압출장치의 설명도, 제6도는 세포주위에 PEG 400 디아크릴레이트의 레이저 중합에 의해 제조된 마이크로캡슐의 현미경 사진, 제7도(가)는 쥐에 i.p. 이식한지 3일후에 회복되는 알기네이트 -PLL 마이크로캡슐의 현미경 사진, 제7도(나)는 제1도에 도시한 염료확산방법을 사용하여 PEG 18.5K Da 테트라아크릴레이트를 코팅한 알기네이트-PLL 마이크로캡슐의 현미경 사진, 제8도는 PEO코팅겔 구성 성분과 쥐의 복막강 세척으로 부터 얻어진 비결합 세포에 대한 세포수와 겔구성비의 관계그래프; a-18.5K; b-10% 0.5K, 90% 18.5K; C-50% 18.5K, 50% 0.4K; d-10% 0.4K, 90% 35K, e-50% 0.4K, 50% 35K f-알기네이트-폴리 L- 리신 대조표준.

Claims (50)

  1. a) 적어도 두개의 자유라디칼 중합가능 치환체를 포함하여 구성되며 비독성이고 분자량이 적어도 400인 수용성 생체상용성 매크로머; 생물학적 물질; 및 가시광선 또는 장파장 자외선 활성화 자유라디칼 개시제, 열활성화 자유라디칼 개시제, 벤조일 퍼옥시드, 포타시움 퍼술페이트와 암모니움 퍼술페이트중에서 선택되는 비독성 자유라디칼 중합개시제를 혼합하여 혼합물을 제조하는 단계. b) 상기 혼합물을 활성화제에 노출시켜 머크로머를 중합하는 단계를 포함하는 생물학적 물질의 캡슐화, 밀봉, 플러깅(plugging)또는 지지방법.
  2. 제1항에 있어서, 상기 생물학적 물질은 포유동물 세포, 세포 집합체, 및 세포 조직중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  3. 제1항에 있어서, 상기 생물학적 활성인 분자는 아미노산이 100개 미만인 펩타이드, 100개 이상 아미노산으로 된 단백질, 폴리사카리드, 핵산, 유기약품, 및 무기약품 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  4. 제1항에 있어서, 상기 자유라디칼 중합가능체는 탄소와 탄소를 연결하는 이중결합 또는 삼중결합을 포함하는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  5. 제1항에 있어서, 상기 혼합물 제조단계에 비독성 촉매 또는 촉진제가 추가되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  6. 제1항에 있어서, 상기 수용성 머크로머는 폴리에틸렌글리콜, 폴리에틸렌옥시드, 폴리비닐알콜, 폴리비닐피롤리돈, 폴리에틸 옥사졸린, 폴리아미노산, 폴리사카라이드, 단백질, 및 이들의 블록 또는 공중합체로 둘이상의 중합가능 치환체를 포함하는 것들 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  7. 제6항에 있어서, 상기 폴리사카리드는 알기나트, 히아루로닉산, 콘드로이틴 술페이트, 댁스트란, 댁스트란 술페이트, 헤파린, 헤파린술페이트, 헤파란 술페이트, 키토산, 겔란검, 크산탄검, 구아검, 및 K-카라기난으로부터 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  8. 제6항에 있어서, 상기 단백질은 겔라틴, 콜라겐 및 알부민 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  9. 제1항에 있어서, 개시제는 열개시제이고 개시원인은 온도의 변화인 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  10. 제1항에 있어서, 상기 자유라디칼 중합가능 치환체를 둘이상의 아크릴레이트 그룹들을 포함하는 머크로머들 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  11. 제1항에 있어서, 겔은 아크릴레이트로 종결된 폴리에틸렌글리콜을 포함하는 머크로머들로 부터 제조되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  12. 제1항에 있어서, 상기 중합개시제는 에오신염료, 치환된 에오신염료, 리보플라빈, 아세토페논, 치환된 아세토페논, 플로오로세인 염료, 치환된 플루오로세인염료, 캄포퀴논, 로즈벤갈, 메틸렌 그린, 메틸렌 블루, 에오신 와이, 에틸 에오신, 아크리딘 오렌지, 크산틴 염료, 및 티오크산틴 염료로 부터 선택되는 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  13. 제1항에 있어서, 상기 중합개시제는 에리트로신, 플록심 및 티오닌으로부터 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  14. 제5항에 있어서, 상기 촉매 또는 촉진제는 아민인 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  15. 제14항에 있어서, 상기 아민은 트리에탄올아민, 트리에틸아민, 에타놀아민, N-메틸너에탄올아민, N,N-미메틸벤질아민, 디벤질아민, N-벤질에탄올아민, N-아소프로필 벤질아민, 테트라메틸 에틸렌-너아민, 리신, 오르니틴, 히스티런 및 아르기닌 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  16. 제1항에 있어서, 중합은 320∼800mm 파장의 광에 의해서 개시되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  17. 제16항 또는 제2항에 있어서 광선은, 514nm 또는 365nm인 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  18. 제2항에 있어서, 상기 포유동물세포, 포유동물 세포 집합체, 또는 포유동물 세포조직은 광민강성 광개시제에 접촉되어 광개시제가 포유동물세포, 포유동물 세포 집합체, 또는 포유동물 세포조직에 결합되도록 하고 비결합 개시제는 그것을 포리머 또는 올리고머에 접촉시키기에 앞서 제거되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  19. 제18항에 있어서, 상기 비결합개시제는 머크로머용액으로 희석시키므로써 제거시켜서 중합이 단지 포유동물세포, 포유동물 세포 집합체 또는 포유동물 조직의 표면에서만 일어나는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  20. 제1항에 있어서, 머크로머 용액이 형성되고 다음에 중합되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  21. 제1항에 있어서, 겔은 지지구조를 포함하는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  22. 제1항에 있어서, 캡슐화된 물질의 주위에 요구되는 투과성이 나타나도록 폴리머가 선정되고 중합이 제어되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  23. 제1항에 있어서, 머크로머 용액의 중합은 세포의 조직을 세포의 너른 조직에 점착시키는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  24. 제2항에 있어서, 생물학적으로 활성인 물질은 세포난 조직으로 캡슐화 되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  25. 제1항에 있어서, 광중합 가능 포리카티온은 겔은 분자난 물질에 대한 부착성을 증대시키도록 캡슐화 되어 있는 분자 꼬는 물질에 미리 흡착되는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  26. 제1항에 있어서, 머크로머 용액은 조직내강에 적용된 후 중합되어서 조직내강의 표면상에 피복 또는 지지체를 형성하는 것을 특징으로 하는 생물학적 물질의 캡슐화, 밀봉, 플러깅 또는 지지방법.
  27. a) i) 적어도 두개의 자유라디칼 중합가능 치환체를 포함하여 구성되며 비독성이고 분자량이 적어도 400인 수용성 생체상용성 머크로머; 생물학적 물질; 및 가시광선 또는 장파장 자외선 활성화 자유라디칼 개시제, 열활성화 자유라디칼 개시제, 벤조일 퍼옥시드, 포타사움 퍼술페이트와 암모니움 퍼술페이트중에서 선택되는 비독성 자유라디칼 중합개시제를 혼합하여 혼합물을 제조하는 단계, b) 상기 혼합물을 활성화제에 노출시켜 머크로머를 중합하는 단계를 포함하는 생체상용성 기질 제조방법.
  28. 제27항에 있어서, 상기 혼합물 단계에 촉매 또는 촉진제가 추가되는 것을 특징으로 하는 생체상용성 기질 제조방법.
  29. 제27항에 있어서, 기질은 마이크로스피어, 멤브란, 직조된 매트릭스, 다공성 매트릭스 및 의치 임플란트 중에서 선택되는 것을 특징으로 하는 생체상용성 기질 제조방법.
  30. 제27항에 있어서, 기질은 개시제로 처리됨과, 비결합 개시제가 제거되며 머크로머가 기질에 적용되어 중합되는 것을 특징으로 하는 생체상용성 기질 제조방법.
  31. 가시광선 또는 장파장 자외선 활성화 자유라디칼 개시제, 열활성화 자유라디칼 개시제, 벤조일 퍼옥시트, 기질에 적용된 적어도 두개의 자유라디칼 중합가능 치환체를 포함하는 수용성 머크로머의 포타시움 퍼술페이트 및 암모니움 퍼술페이트 중에서 선택되는 개시제를 사용하는 자유라디칼 중합에 의해 형성된 고분자 코팅을 가지는 기질 제조방법.
  32. 적어도 두개의 자유라디칼 중합가능 치환체가 공유 결합된 생체상용성 수용성 머크로머의 자유라디칼 중합에 의해 제조되는 고분자로 이루어진 조직내강 상의 코팅장치.
  33. 제32항에 있어서, 상기 조직내강은 혈관인 것을 특징으로 하는 코팅장치.
  34. a) 세포나 조직에 광개시제를 적용하는 단계, b) 비경합 광개시제를 제거하는 단계, c) 적어도 두개의 자유라디칼 중합가능 치환체를 포함하는 수용성 머크로머 용액을 세포 또는 조직에 적용하는 단계, d) 상기 용액을 가시광선 또는 장파장 자외선을 노출시키는 단계를 포함하는 조직 또는 세포의 고분자 코팅방법.
  35. 생물학적 물질의 캡슐화 방법으로서, a) 광개시제; 및 폴리에틸렌 옥시드, 폴리에틸렌 글리콜멀티아크릴레이트를 포함하는 폴리에틸렌 글리콜, 폴리비닐알콜, 폴리비닐피롤리돈, 폴리에틸옥사졸린, 폴리아미노산, 알기나트와 히아루로닉산과 콘드로이틴 술페이트와 댁스트란과 댁스트린술페이트와 키토산과 겔란검과 크산탄검과 구아검과 수용성 셀룰로스 유도체 및 카라기난으로 부터 선택되는 폴리사카리드, 및 겔라틴과 콜라젠과 알부민으로 부터 선택되는 단백질로 구성되는 그룹의 유도체로 부터 선택되는 적어도 두개의 탄소와 탄소사이의 이중결합의 상호작용을 통하여 수불용성 고분자로 중합되는 수용성 불포화 에틸렌성 고분자로 부터 선택되는 머크로머를 포함하는 머크로머 수용액중에 생물학적 물질을 혼합하는 단계, b) 공기와 동시압출이나, 방울형태를 유지할 수 있는 광물성 기름과 같은 비독성, 비면역성, 비혼화성물질과 동시 압출 또는 교반하여 (a) 혼합물에 작은 공형태들을 형성시키는 단계, c) 상기 공모양 물질에 광을 노출시켜 머크로머를 중합하는 단계를 포함하는 생물학적 물질의 캡슐화 방법.
  36. 제35항에 있어서, 상기 폴리에틸렌 글리콜(PEG)는 분자량이 18.500D 가량인 PEG 테트라아크릴레이트인 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  37. 제35항에 있어서, 상기 광개시제는 2,2-디메톡시, 2-페닐-아세토페논과 2-메톡시, 2-페닐아세토페논을 포함하여 320∼900nm정도 파장의 빛을 흡수하고, 자유라디칼을 형성할 수 있으며, 적어도 부분적 수용성을 물질에 대해 독성이 없는 염료인 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  38. 제35항에 있어서, 상기 머크로머 용액은 트리에타놀아민, 트리에틸아민, 에탄올아민, N-메틸디에탄올아민, N,N-디메틸벤질아민, 디벤질아민, N,N-디메틸벤질아민, 디벤질아민, N-벤질에탄올아민, N-이소프로필벤질아민, 테트라메틸에틸렌디아민, 포타시움퍼술페이트, 테트라메틸에틸렌디아민, 리신, 오르니틴, 히스티딘 및 아르기닌과 같은 1차, 2차, 3차 및 제4차 아민을 포함하는 자유라디칼 반응을 자극할 수 있는 질소를 기본으로 하는 화합물이 포함된 공촉매를 추가로 함유하고, 상기 공개시제는 에틸에오신, 에오신와이, 플루오테세인, 2,2-디메톡시, 2-페닐아세토페논, 2-메톡시, 2-페닐아세토페논, 캄포퀴논, 로즈벤갈, 메틸렌블루, 에리트로신, 플록신, 티오네인, 리보플라민 및 메틸렌 그린에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  39. 제35항에 있어서, 상기 생물학적 물질은 포유동물 조직과 판크레아틱 이스렛 세포, 사람의 포피 섬유아세포, 중극 햄스터 난소세포, 베타세포 도선종, 임파아구 백혈병세포, 쥐의 3T3 섬유아세포, 도파민 분비 복강 중뇌세포, 신경아세포, 아드레날인 수질세포 및 T세포, 서브세포 기능질, 및 서브세포 비기능질 성분에서 선택되는 포유동물세포의 1차 또는 설립 라인에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  40. 제35항에 있어서, 상기 생물학적 물질은 헤모글로빈, 폴리사카리드 및 올리고누클레오티드를 포함하는 단백질, 아데노신 탈아미드효소, 효소체계, 박테리아, 미생물, 비타민, 조인자 및 혈액응고인자를 포함하는 효소, TPA, 스트랩토키나제 및 헤파린을 포함하는 약품, 이뮤노겐, 호르몬 및 레트로바이러스 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  41. 제35항에 있어서, 상기 생물학적 물질은 먼저 마이크로 캡슐로 캡슐화되고, 상기 마이크로 캡슐은 아르기나트, 키토산, 아가로스, 겔라틴, 또는 이들의 조합들을 포함하는 캡슐화된 물질에 독성이 없는 이온 응고성 또는 열응고성 고분자로 구성되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  42. 제35항에 있어서, 상기 커크로머 용액은 N-비닐피롤리디논, 2-비닐피리딘, 1-비닐이미다졸, 9-비닐카바졸, 아크릴산 및 2-알릴, 2-메틸, 1-3-시클로펜탄디온을 포함하는 알릴, 비닐 또는 아크릴레이트 그룹을 가지는 작은 분자를 포함하는 중합촉진제를 추가로 함유하는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  43. a) 생물학적 물질을 광개시제로 코팅하는 단계, b) 폴리에틸렌옥시드, 폴리에틸렌 글리콜 멀티아크릴레이트를 포함하는 폴리에틸렌글리콜, 폴리비닐알콜, 폴리비닐피롤리돈, 폴리에틸옥사졸린, 폴리아미노산, 알기나트와 히아루로닉산과 콘드로이틴술페이트와 댁스트란과 댁스트란술페이트와 헤파린과 헤파린술페이트와 헤파란술페이트와 키토산과 겔라검과 크산탄검과 구아검과 수용성 셀룰로스 유도체 및 카라기난으로 부터 선택되는 폴리사카리드, 및 겔라틴과 콜라젠과 알부민으로 부터 선택되는 단백질로 구성되는 그룹의 유도체로 부터 선택되는 적어도 두개의 탄소와 탄소사이의 이중결합의 상호작용을 통하여 수불용성 고분자로 중합되는 수용성 불포화 에틸렌성 고분자로 부터 선택되는 머크로머를 포함하는 머크로머 수용액중에 코팅된 물질을 현탁시키는 단계, c) 현탁물에 광조사하여 머크로머를 중합하는 단계를 포함하는 생물학적 물질의 캡슐화 방법.
  44. 제43항에 있어서, 상기 폴리에틸렌글리콜(PEG)은 분자량이 18,500P가량의 PEG 테트라아크릴레이트인 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  45. 제43항에 있어서, 상기 광개시제는 2,2-디메톡시, 2-페닐-아세토페논과 2-메톡시, 2-페닐아세토페논을 포함하여 320∼900nm정도 파장의 빚을 흡수하고, 자유라디칼을 형성할 수 있으며, 적어도 부분적 수용성을 나타내며 중합에 사용되는 농도에서 생물학적 물질에 대해 독성이 없는 염료인 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  46. 제43항에 있어서, 상기 머크로머 용액은 트리에타놀아민, 트리에틸아민, 에탄올아민, N-메틸디에탄올아민, N,N-디메틸 벤질아민, 디벤질아민, N-벤질에탄올아민, N-이소프로필 벤질아민, 테트라메틸에틸렌디아만, 포타시움 퍼술페이트, 테트라메틸 에틸렌디아민, 리신, 오르니틴, 히스티딘 및 아르기닌과 같은 1차, 2차, 3차 및 제4차 아민을 포함하는 자유라디칼 반응을 자극할 수 있는 질소를 기본으로 하는 화합물이 포함된 공촉매를 추가로 함유하고, 상기 광개시제는 에틸에오신, 에오신와이, 플루오레세인, 2,2-디메톡시, 2-페닐아세토페논, 2-메톡시, 2-페닐아세토페논, 캄포퀴논, 로즈벤갈, 메틸렌블루, 에리트론신, 플록신, 티오네인, 리보플라빈 및 메틸렌 그린에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  47. 제43항에 있어서, 상기 생물학적 물질은 포유동물 조직과 판크레아틱 이스렛 세포,사람의 포피 섬유아세포, 중극 햄스터 난소세포, 베타세포 도선종, 임파아구 백혈병세포, 쥐의 3T3 섬유아세포, 도파민 분비 복강 중뇌세포, 신경아세포, 아드레날인 수질세포 및 T세포, 서브세포 기능질, 및 서브세포 비기능질 성분에서 선택되는 포유동물세포의 1차 또는 설립 라인에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  48. 제43항에 있어서, 상기 생물학적 물질은 헤모글로빈, 폴리사카리드 및 올리고누클레오티드를 포함하는 단백질, 아데노신 탈아미드효소, 효소체계, 박테리아, 미생물, 비타민, 조인자 및 혈액응고인자를 포함하는 효소, TPA, 스트랩토키나제 및 헤파린을 포함하는 약품, 이뮤노겐, 호르몬 및 레트로바이러스 중에서 선택되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  49. 제43항에 있어서, 상기 생물학적 물질은 먼저 마이크로 캡슐로 캡슐화되고, 상기 마이크로 캡슐은 아르기나트, 키토산, 아가로스, 겔라틴, 또는 이들의 조합들을 포함하는 캡슐화된 물질에 독성이 없는 이온 응고성 또는 열응고성 고분자로 구성되는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
  50. 제43항에 있어서, 상기 커크로머 용액은 N-비닐피롤리디논, 2-비닐피리딘, 1-비닐이미다졸, 9-비닐카바졸, 아크릴산 및 2-알릴, 2-메틸, 1-3-시클로펜탄디온을 포함하는 알릴, 비닐 또는 아크릴레이트 그룹을 가지는 작은 분자를 포함하는 중합촉진제를 추가로 함유하는 것을 특징으로 하는 생물학적 물질의 캡슐화 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703035A 1992-02-28 1994-08-29 생물학적물질의캡슐화를위한고분자겔 KR100323043B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US84348592A 1992-02-28 1992-02-28
US843,485 1992-02-28
US87054092A 1992-04-20 1992-04-20
US870,540 1992-04-20
US958,870 1992-10-07
US07/958,870 US5529914A (en) 1990-10-15 1992-10-07 Gels for encapsulation of biological materials

Publications (2)

Publication Number Publication Date
KR950700054A true KR950700054A (ko) 1995-01-16
KR100323043B1 KR100323043B1 (ko) 2002-07-27

Family

ID=27420310

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703035A KR100323043B1 (ko) 1992-02-28 1994-08-29 생물학적물질의캡슐화를위한고분자겔

Country Status (14)

Country Link
US (4) US5529914A (ko)
EP (1) EP0627912B1 (ko)
JP (1) JP3011767B2 (ko)
KR (1) KR100323043B1 (ko)
AT (1) ATE266389T1 (ko)
AU (1) AU683209B2 (ko)
BR (1) BR9306041A (ko)
CA (1) CA2117584C (ko)
DE (1) DE69333512T2 (ko)
DK (1) DK0627912T3 (ko)
ES (1) ES2220906T3 (ko)
NZ (1) NZ251039A (ko)
PT (1) PT627912E (ko)
WO (1) WO1993016687A1 (ko)

Families Citing this family (395)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US20040195710A1 (en) * 1990-10-15 2004-10-07 Hubbell Jeffrey A. Gels for encapsulation of biological materials
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
EP0627911B1 (en) * 1992-02-28 2000-10-25 Board Of Regents The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5800373A (en) * 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5749968A (en) * 1993-03-01 1998-05-12 Focal, Inc. Device for priming for improved adherence of gels to substrates
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5698189A (en) * 1993-03-23 1997-12-16 Focal, Inc. Method for local application of polymeric material to tissue
US6004547A (en) 1997-09-29 1999-12-21 Focal, Inc. Apparatus and method for local application of polymeric material to tissue
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5453368A (en) * 1993-08-27 1995-09-26 Brown University Research Foundation Method of encapsulating biological substances in microspheres
US5994318A (en) * 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6703017B1 (en) 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5665063A (en) 1994-06-24 1997-09-09 Focal, Inc. Methods for application of intraluminal photopolymerized gels
DE4426396A1 (de) * 1994-07-26 1996-02-01 Ulrich Prof Dr Zimmermann Verfahren zur Herstellung konzentrierter Lösungen von mikroverkapselten Zellen oder von suspendierten Wirkstoffen in mikroverkapselter Form
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5931165A (en) * 1994-09-06 1999-08-03 Fusion Medical Technologies, Inc. Films having improved characteristics and methods for their preparation and use
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
AU709527B2 (en) * 1995-03-23 1999-09-02 Board Of Regents, The University Of Texas System Redox and photoinitiator systems for priming for improved adherence of gels to substrates
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
AU704222B2 (en) 1995-03-24 1999-04-15 Genzyme Corporation Reduction of adhesions using controlled delivery of active oxygen inhibitors
GB9506844D0 (en) * 1995-04-03 1995-05-24 Armitage Ian M Pharmaceutical microencapsulation
FR2733230B1 (fr) * 1995-04-20 1997-05-30 Oreal Nouveaux derives d'ornithine, procede de preparation, utilisation et composition les comprenant
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
DE19519804A1 (de) * 1995-05-31 1996-12-05 Juergen Dr Schrezenmeir Bioaktive Kapsel mit veränderlicher Hülle
US5827707A (en) * 1995-06-07 1998-10-27 Neocrin Company Method for manufacturing minimal volume capsules containing biological materials
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US5779673A (en) * 1995-06-26 1998-07-14 Focal, Inc. Devices and methods for application of intraluminal photopolymerized gels
WO1997013461A1 (en) * 1995-10-11 1997-04-17 Fusion Medical Technologies, Inc. Device and method for sealing tissue
EP1586284B1 (en) * 1995-10-26 2009-02-18 Paul P. Latta Induction of immunological tolerance
WO1997017038A1 (en) * 1995-11-09 1997-05-15 University Of Massachusetts Tissue re-surfacing with hydrogel-cell compositions
CN1052915C (zh) * 1995-11-27 2000-05-31 中国医学科学院生物医学工程研究所 用于携载基因的蛋白质涂层医用载体及其制作方法
US5908624A (en) * 1996-06-27 1999-06-01 Albany Medical College Antigenic modulation of cells
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5791352A (en) * 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US6696499B1 (en) * 1996-07-11 2004-02-24 Life Medical Sciences, Inc. Methods and compositions for reducing or eliminating post-surgical adhesion formation
US6721083B2 (en) * 1996-07-19 2004-04-13 E Ink Corporation Electrophoretic displays using nanoparticles
US20090324721A1 (en) * 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6566406B1 (en) * 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
BR9711537B1 (pt) * 1996-09-23 2010-12-14 macrâmero polimerizÁvel biodegradÁvel, mÉtodo para aumentar a elasticidade de um gel de polÍmero hidrofÍlico e mÉtodo para melhorar a biodegradabilidade de um macrâmero quimicamente reativo compreendendo carbonato.
US7009034B2 (en) * 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
AU4648697A (en) * 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
AU6769098A (en) * 1997-03-20 1998-10-12 Focal, Inc. Biodegradable tissue retractor
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
US6127520A (en) * 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
EP0975691B1 (en) * 1997-04-21 2010-10-13 California Institute Of Technology Multifunctional polymeric coatings
US6015474A (en) 1997-06-20 2000-01-18 Protein Polymer Technologies Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants
US6211249B1 (en) * 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US5837752A (en) * 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
CA2296459A1 (en) 1997-07-18 1999-01-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
EP1512395A1 (en) * 1997-07-18 2005-03-09 Azopax Therapeutics LLC Biodegradable macromers for the controlled release of biologically active substances
JP4302877B2 (ja) 1997-07-30 2009-07-29 エモリー・ユニバーシテイ 新規な骨鉱化蛋白質、ｄｎａ、ベクター及び発現系
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
AU8681098A (en) 1997-08-01 1999-03-08 Massachusetts Institute Of Technology Three-dimensional polymer matrices
US6162241A (en) * 1997-08-06 2000-12-19 Focal, Inc. Hemostatic tissue sealants
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6316522B1 (en) 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6458357B1 (en) 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
IL135800A0 (en) 1997-10-27 2001-05-20 Univ California Methods and pharmaceutical compositions for the closure of retinal breaks
US6872387B1 (en) 1998-02-24 2005-03-29 The Regents Of The University Of Michigan Three-dimensional hydrogel/cell system
US6096726A (en) 1998-03-11 2000-08-01 Surface Solutions Laboratories Incorporated Multicomponent complex for use with substrate
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US20020156434A1 (en) * 1998-03-13 2002-10-24 Minimed Inc. Stabilizing catheter for protein drug delivery
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
US7547445B2 (en) * 1998-03-19 2009-06-16 Surmodics, Inc. Crosslinkable macromers
AU768179B2 (en) * 1998-03-19 2003-12-04 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
US6007833A (en) * 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
DE19818360C2 (de) * 1998-04-24 2000-05-31 Suisse Electronique Microtech Dextranbeschichtete Oberfläche
US6027744A (en) * 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
ES2179646T3 (es) 1998-04-27 2003-01-16 Surmodics Inc Revestimiento que libera un agente bioactivo.
US5998534A (en) * 1998-06-19 1999-12-07 Ppg Industries Ohio, Inc. Water-soluble or water-dispersible addition copolymer
EP1095076A4 (en) * 1998-07-08 2002-11-06 Sunsoft Corp INTERMEDIATE POLYMERS NETWORK OF HYDROPHILIC HYDROGELS FOR CONTACT LENSES
EP1098696B2 (de) † 1998-07-15 2010-07-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polyelektrolythüllen auf biologischen templaten
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US7347850B2 (en) * 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
WO2000016621A1 (en) 1998-09-24 2000-03-30 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6022361A (en) * 1998-10-09 2000-02-08 Biointerventional Corporation Device for introducing and polymerizing polymeric biomaterials in the human body and method
CA2345982A1 (en) * 1998-10-12 2000-04-20 Jill K. Sherwood Composites for tissue regeneration and methods of manufacture thereof
US20030099682A1 (en) * 1998-11-20 2003-05-29 Francis Moussy Apparatus and method for control of tissue/implant interactions
CA2351734A1 (en) 1998-11-20 2000-06-02 University Of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6864301B2 (en) * 1998-11-30 2005-03-08 The Regents Of The University Of Colorado Preparation and use of photopolymerized microparticles
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
ES2632564T3 (es) 1999-02-01 2017-09-14 Eidgenössische Technische Hochschule Zürich Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6605391B2 (en) * 1999-02-26 2003-08-12 Reveo, Inc. Solid gel membrane
US6358651B1 (en) * 1999-02-26 2002-03-19 Reveo, Inc. Solid gel membrane separator in rechargeable electrochemical cells
US6849702B2 (en) * 1999-02-26 2005-02-01 Robert W. Callahan Polymer matrix material
WO2000051538A1 (en) 1999-03-01 2000-09-08 Uab Research Foundation Porous tissue scaffolding materials and uses thereof
US6495161B1 (en) * 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
AU4173000A (en) * 1999-03-19 2000-10-09 Regents Of The University Of Michigan, The Mineralization and cellular patterning on biomaterial surfaces
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
WO2000060956A1 (en) * 1999-04-12 2000-10-19 Cornell Research Foundation, Inc. Hydrogel-forming system with hydrophobic and hydrophilic components
EP1190252B1 (en) * 1999-04-28 2008-12-31 Eidgenössische Technische Hochschule Zürich Polyionic coatings in analytic and sensor devices
US20060247665A1 (en) 1999-05-28 2006-11-02 Ferree Bret A Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft
US20070038231A1 (en) 1999-05-28 2007-02-15 Ferree Bret A Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft
US7273497B2 (en) 1999-05-28 2007-09-25 Anova Corp. Methods for treating a defect in the annulus fibrosis
US6579951B1 (en) * 1999-06-08 2003-06-17 Life Medical Sciences, Inc. Chain-extended or crosslinked polyethylene oxide/polypropylene oxide/polyethylene oxide block polymer with optional polyester blocks
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
JP2001048978A (ja) 1999-08-04 2001-02-20 Nano Career Kk オキサゾリン由来のポリマーセグメントを有するブロックコポリマー
US6719797B1 (en) 1999-08-13 2004-04-13 Bret A. Ferree Nucleus augmentation with in situ formed hydrogels
US7056503B2 (en) * 1999-08-19 2006-06-06 Regents Of The University Of Michigan Enclosures housing cell-coated supports for treating tumors
CA2385628A1 (en) * 1999-09-27 2001-04-05 Ammon B. Peck Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6521284B1 (en) * 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
US6861001B2 (en) * 1999-12-02 2005-03-01 The General Hospital Corporation Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
JP2001208754A (ja) * 2000-01-26 2001-08-03 Kazunori Kataoka 生物学的な被検体を検出するための組成物
US20030095993A1 (en) * 2000-01-28 2003-05-22 Hanne Bentz Gel-infused sponges for tissue repair and augmentation
US7039453B2 (en) * 2000-02-08 2006-05-02 Tarun Mullick Miniature ingestible capsule
DE60115212T2 (de) * 2000-03-13 2006-07-27 Biocure, Inc. Biomedizinische artikel aus hydrogel
US6652883B2 (en) * 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
CA2403218C (en) 2000-03-13 2011-10-18 Biocure, Inc. Embolic compositions
US8642051B2 (en) 2000-03-21 2014-02-04 Suzanne Jaffe Stillman Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s)
US20020013261A1 (en) * 2000-05-18 2002-01-31 Robert Pawliuk Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DE10031132A1 (de) * 2000-06-30 2002-01-17 Henkel Kgaa Verfahren zur Herstellung aktivstoffhaltiger Kapseln mit ultradünner Wandschicht
EP1193056A1 (en) * 2000-09-29 2002-04-03 International Business Machines Corporation Silicone elastomer stamp with hydrophilic surfaces and method of making same
US7132475B2 (en) * 2000-10-19 2006-11-07 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems
KR100380569B1 (ko) * 2000-10-24 2003-04-26 주식회사 메디프렉스 고분자 결합을 이용한 췌장소도 막의 표면개질 방법
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
FR2816847B1 (fr) * 2000-11-22 2006-07-14 Assist Publ Hopitaux De Paris Biomateriaux polymeriques poreux, procede de preparation et utilisations
US6596471B2 (en) * 2000-12-21 2003-07-22 Carbomedics Inc. Method of cross-linking tissue with a bis-maleimide compound
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US7771468B2 (en) 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
WO2002074354A1 (en) * 2001-03-16 2002-09-26 Delsitech Oy Treatment of sols, gels, mixtures or composites of sols and gels, and/or sol-gel derived materials
FI20010523A0 (fi) * 2001-03-16 2001-03-16 Yli Urpo Antti Soolien, geelien ja niiden seosten käsittely
WO2002074158A2 (en) * 2001-03-20 2002-09-26 Eidgenossische Technische Hochschule Zurich Two-phase processing of thermosensitive polymers for use as biomaterials
MXPA03011263A (es) * 2001-06-07 2004-02-26 Surmodics Inc Macromeros reticulables.
US8101196B2 (en) * 2001-06-26 2012-01-24 Biointeractions, Ltd. Polysaccharide biomaterials and methods of use thereof
US6685927B2 (en) * 2001-09-27 2004-02-03 Ceramoptec Industries, Inc. Topical application of chromophores for hair removal
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
FR2833961B1 (fr) * 2001-12-20 2004-04-02 Virsol Procede de preparation de films a base de poly(oxyde d'ethylene) reticule
AU2003207508A1 (en) * 2002-01-10 2003-07-30 Northeastern University Hybrid immobilized catalytic system with controlled permeability
AU2003216379A1 (en) * 2002-02-22 2003-09-09 Control Delivery Systems, Inc. Method for treating otic disorders
ITPD20020064A1 (it) * 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
US6616954B1 (en) * 2002-03-14 2003-09-09 Balchem Corporation Solvent released encapsulated yeast
US20030179692A1 (en) * 2002-03-19 2003-09-25 Yoshitaka Ohotomo Storage medium
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
US7419947B2 (en) * 2002-03-27 2008-09-02 Novozymes A/S Process for preparing granules with filamentous coatings
AU2003232536A1 (en) * 2002-05-07 2003-11-11 Mcmaster University Microcapsules containing biomedical materials
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
US7217254B2 (en) 2002-09-20 2007-05-15 Genzyme Corporation Multi-pressure biocompatible agent delivery device and method
US7862831B2 (en) * 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US20050069572A1 (en) * 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
WO2004032881A2 (en) * 2002-10-11 2004-04-22 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
US7816316B2 (en) * 2002-11-21 2010-10-19 Chugai Seiyaku Kabushiki Kaisha Sustained release drug carrier
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN100341484C (zh) * 2003-01-16 2007-10-10 康乃尔研究基金会有限公司 部分可生物降解的温度和pH敏感的水凝胶
EP1631375B1 (en) * 2003-01-17 2011-11-02 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
US7393493B2 (en) * 2003-02-27 2008-07-01 A Enterprises, Inc. Crosslinkable polymeric materials and their applications
US20060052471A1 (en) * 2003-02-27 2006-03-09 A Enterprises, Inc. Initiators and crosslinkable polymeric materials
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US7585499B2 (en) * 2003-04-10 2009-09-08 Surmodics, Inc. Method for encapsulation of cellular material using a charged initiator polymer
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
ES2380093T3 (es) * 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
US7251893B2 (en) * 2003-06-03 2007-08-07 Massachusetts Institute Of Technology Tribological applications of polyelectrolyte multilayers
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CN1879065A (zh) * 2003-09-12 2006-12-13 弗尔克斯破产财产公司 用于生物活性剂的定位传递的包含磁性成分和生物相容性聚合物的可磁靶向颗粒
US20050282747A1 (en) * 2003-10-01 2005-12-22 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for wound healing
CA2445363C (en) * 2003-10-17 2012-05-22 Francois Leblond Semi-permeable microcapsule with covalently linked layers and method for producing same
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7846333B2 (en) * 2003-11-24 2010-12-07 Effendorf AG Porous media
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US8202833B2 (en) * 2003-11-26 2012-06-19 Surmodics, Inc. Composition containing biocompatible polymerization accelerator and polymerizable material
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005061018A1 (en) 2003-12-22 2005-07-07 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring protein backbone
US7842667B2 (en) * 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US7846137B2 (en) * 2003-12-26 2010-12-07 Medtronic Minimed, Inc. Modular catheter system
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
NZ548123A (en) * 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
WO2005072764A2 (en) * 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US20050202096A1 (en) * 2004-03-09 2005-09-15 Jun Li Microcapsules for encapsulation of bioactive substances
US7205145B2 (en) * 2004-03-24 2007-04-17 Zefon International, Inc. Gas-borne matter collection device
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
US7566747B2 (en) * 2004-05-07 2009-07-28 The Board Of Trustees Of The University Of Illinois Wax particles for protection of activators, and multifunctional autonomically healing composite materials
US20050266415A1 (en) * 2004-05-28 2005-12-01 Zefon International, Inc. Method for sampling gas-borne matter
US20050271727A1 (en) * 2004-06-07 2005-12-08 Callisyn Pharmaceuticals, Inc. Biodegradable and biocompatible crosslinked polymer hydrogel prepared from PVA and/or PEG macromer mixtures
US7723086B2 (en) * 2004-06-16 2010-05-25 Agency For Science, Technology + Research Apparatus for encapsulating cells
AU2005260645B2 (en) * 2004-06-29 2010-12-09 Biocure, Inc. Spinal disc nucleus pulposus implant
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
NZ553149A (en) * 2004-08-12 2010-01-29 Quest Pharmaceutical Services Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions
US7919112B2 (en) * 2004-08-26 2011-04-05 Pathak Holdings, Llc Implantable tissue compositions and method
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
CA2583826A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US20060239986A1 (en) * 2005-01-26 2006-10-26 Perez-Luna Victor H Method for the formation of hydrogel multilayers through surface initiated photopolymerization
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2595633C (en) * 2005-02-09 2013-11-19 Ahmad R. Hadba Synthetic sealants
JP2008529749A (ja) * 2005-02-18 2008-08-07 シンタソーム インコーポレーテッド 軟組織修復用合成構造物
WO2006099137A1 (en) * 2005-03-10 2006-09-21 Uab Research Foundation Endothelial predecessor cell seeded wound healing scaffold
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
US20060222596A1 (en) 2005-04-01 2006-10-05 Trivascular, Inc. Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US7612152B2 (en) * 2005-05-06 2009-11-03 The Board Of Trustees Of The University Of Illinois Self-healing polymers
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1891141B1 (en) * 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
CN101222902A (zh) * 2005-06-15 2008-07-16 苏尔莫迪克斯公司 包括光激活的引发剂的大分子单体组合物
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007048105A2 (en) * 2005-10-19 2007-04-26 A Enterprises, Inc. Curable bone substitute
WO2007053794A2 (en) 2005-10-21 2007-05-10 Bezwada Biomedical Llc Functionalized phenolic compounds and absorbable therefrom
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
TWI285100B (en) * 2005-12-27 2007-08-11 Ind Tech Res Inst Surface modification of polysaccharide, the modified polysaccharide, and method of culturing and recovery cells using the same
US20070149641A1 (en) * 2005-12-28 2007-06-28 Goupil Dennis W Injectable bone cement
EP1973972A2 (en) 2006-01-05 2008-10-01 The Board Of Trustees Of The University Of Illinois Self-healing coating system
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US20070212385A1 (en) * 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
DE102006014862A1 (de) * 2006-03-30 2007-10-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Abdeckmaterial für Biomasse und Verfahren zu dessen Herstellung
US20070237749A1 (en) * 2006-04-07 2007-10-11 Wang Taylor G Multi-membrane immunoisolation system for cellular transplant
JP6075930B2 (ja) 2006-04-24 2017-02-08 インセプト エルエルシー タンパク質架橋剤、架橋方法及びその用途
WO2010062971A1 (en) 2008-11-26 2010-06-03 Anova Corporation Methods and apparatus for anulus repair
US7872068B2 (en) * 2006-05-30 2011-01-18 Incept Llc Materials formable in situ within a medical device
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
US20070280986A1 (en) * 2006-06-01 2007-12-06 Carlos Gil Intra-operative coating of implants
US7569625B2 (en) * 2006-06-02 2009-08-04 The Board Of Trustees Of The University Of Illinois Self-healing elastomer system
US8834496B2 (en) 2006-06-13 2014-09-16 Bret A. Ferree Soft tissue repair methods and apparatus
US8764835B2 (en) 2006-06-13 2014-07-01 Bret A. Ferree Intervertebral disc treatment methods and apparatus
US9232938B2 (en) 2006-06-13 2016-01-12 Anova Corp. Method and apparatus for closing fissures in the annulus fibrosus
WO2007147087A2 (en) * 2006-06-14 2007-12-21 Brigham Young University Adsorption-resistant acrylic copolymer for fluidic devices
FR2902661B1 (fr) * 2006-06-22 2011-05-13 Orthomed Tubes de collagene
KR101299485B1 (ko) * 2006-07-06 2013-08-29 가부시키가이샤 히다찌 플랜트 테크놀로지 포괄 고정화 담체, 포괄 고정화 담체를 이용한 폐수처리 장치 및 폐수처리 방법
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100215720A1 (en) 2006-08-08 2010-08-26 Fundacion Inasmet Implantable optical system, method for developing it and applications
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
KR100783228B1 (ko) 2006-08-29 2007-12-06 가톨릭대학교 산학협력단 세포배양용 폴리비닐알코올-콜라겐 하이드로젤 스캐폴드 및그 제조방법
EP2061483A1 (en) * 2006-09-07 2009-05-27 McGill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
SI2068907T1 (en) 2006-10-04 2018-01-31 Novo Nordisk A/S Pegylated sugars and glycopeptides are associated with glycerol
JP4386061B2 (ja) * 2006-10-06 2009-12-16 株式会社豊田中央研究所 固形複合材料及びその製造方法
US7926368B2 (en) * 2006-11-01 2011-04-19 Zefon International, Inc. Humidity-controlled gas-borne matter collection device
US7935363B2 (en) * 2006-12-12 2011-05-03 Synthasome, Inc. Composite material for tissue repair
US20100196439A1 (en) * 2006-12-22 2010-08-05 Medtronic, Inc. Angiogenesis Mechanism and Method, and Implantable Device
US20080215090A1 (en) * 2007-02-14 2008-09-04 Entrigue Surgical, Inc. Method and System for Tissue Fastening
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20080299391A1 (en) * 2007-05-31 2008-12-04 White Scott R Capsules, methods for making capsules, and self-healing composites including the same
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
CA2698212A1 (en) 2007-08-23 2009-02-26 Intrexon Corporation Methods and compositions for diagnosing disease
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009029049A1 (en) * 2007-08-30 2009-03-05 National University Of Singapore A bone and/or dental cement composition and uses thereof
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8026285B2 (en) 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
US8048980B2 (en) 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
US8093038B2 (en) * 2007-09-17 2012-01-10 Illinois Institute Of Technology Apparatus and method for encapsulating pancreatic cells
EP2185628A1 (en) * 2007-09-25 2010-05-19 SurModics, Inc. Durable swellable hydrogel matrix, method for preparation and method for encapsulation
US8053591B2 (en) 2007-09-26 2011-11-08 Bezwada Biomedical, Llc Functionalized biodegradable triclosan monomers and oligomers for controlled release
US20090088723A1 (en) * 2007-09-28 2009-04-02 Accessclosure, Inc. Apparatus and methods for treating pseudoaneurysms
BRPI0817233A2 (pt) 2007-09-28 2012-11-06 Intrexon Corp construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
US8608049B2 (en) 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US20090123519A1 (en) * 2007-11-12 2009-05-14 Surmodics, Inc. Swellable hydrogel matrix and methods
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090181254A1 (en) * 2008-01-15 2009-07-16 The Board Of Trustees Of The University Of Illinois Multi-capsule system and its use for encapsulating active agents
CN101978040A (zh) * 2008-01-24 2011-02-16 犹他卅大学研究基金会 胶粘复合凝聚物及其制备和使用方法
US8283384B2 (en) 2008-01-24 2012-10-09 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US20090238815A1 (en) * 2008-03-18 2009-09-24 Medtronic Vascular, Inc. Nondegradable Hydrogels For Medical Device Application
EP2271312A4 (en) * 2008-03-19 2013-12-11 Univ Florida NERVOUS REPAIR WITH A HYDROGEL AND AN OPTIONAL ADHESIVE
GB2459438B (en) * 2008-04-10 2010-10-06 Kythera Biopharmaceuticals Inc Systems and methods for transdermal photo-polymerization
CA2722425A1 (en) * 2008-04-28 2009-11-05 Surmodics, Inc. Poly-.alpha.(1-4)glucopyranose-based matrices with hydrazide crosslinking
US9694055B2 (en) * 2008-05-09 2017-07-04 Wake Forest University Health Sciences Renal tissue regeneration
US8367747B2 (en) 2008-05-23 2013-02-05 Bezwada Biomedical, Llc Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof
US20090294049A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Biodegradable Adhesive Hydrogels
US8535644B2 (en) * 2008-10-10 2013-09-17 Massachusetts Institute Of Technology Tunable hydrogel microparticles
WO2010057039A2 (en) 2008-11-14 2010-05-20 Cythera, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
US9198872B2 (en) 2008-12-08 2015-12-01 University Of Miami Dendritic and hyperbranched polymers for cellular encapsulation and functionalization
US8728520B2 (en) * 2008-12-08 2014-05-20 University Of Miami Cross-linked alginate-polyalkylene glycol polymer coatings for encapsulation and methods of making the same
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP3904505A1 (en) 2009-04-22 2021-11-03 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US9597430B2 (en) * 2009-07-31 2017-03-21 Synthasome, Inc. Synthetic structure for soft tissue repair
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
US8810417B2 (en) 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
AU2010319502B2 (en) 2009-11-12 2014-06-12 Vcell Therapeutics, Inc. Subpopulations of spore-like cells and uses thereof
CA3149284A1 (en) 2009-12-15 2011-07-14 Incept, Llc Implants and biodegradable fiducial markers
US20110223314A1 (en) * 2010-03-10 2011-09-15 Xiaoxiao Zhang Efficient microencapsulation
WO2011119607A2 (en) 2010-03-24 2011-09-29 The Board Of Trustees Of The University Of Illinois Viscoelastic ink for direct writing of hydrogel structures
EP2552406B1 (en) * 2010-03-26 2018-01-24 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
MX342912B (es) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
CN103025360A (zh) 2010-05-24 2013-04-03 犹他大学研究基金会 增强的粘合剂复合物凝聚层和其制备和使用方法
US9232805B2 (en) 2010-06-29 2016-01-12 Biocure, Inc. In-situ forming hydrogel wound dressings containing antimicrobial agents
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US9173971B2 (en) 2010-11-12 2015-11-03 University Of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
EP3156480B1 (en) 2011-02-07 2020-03-25 Life Technologies Corporation Compositions and methods for stabilizing susceptible compounds
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3138571A1 (en) 2011-03-04 2017-03-08 Wake Forest University Health Sciences Encapsulated cells for hormone replacement therapy
AU2012242479B2 (en) 2011-04-15 2015-04-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
US10660987B2 (en) 2011-04-29 2020-05-26 Converge Biotech Inc. Conformal coating of cells for immunoisolation
EP2751136B1 (en) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CA2858161C (en) 2011-12-05 2020-03-10 Incept, Llc Medical organogel processes and compositions
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
KR101327630B1 (ko) * 2012-03-05 2013-11-13 울산대학교 산학협력단 아텔로콜라겐을 이용한 췌도세포 이식용 담체의 제조방법 그리고 이를 이용하여 제조된 인공췌장
CN102697731B (zh) * 2012-05-10 2013-12-25 华东医院 5-氨基酮戊酸纳米粒及其制备方法和装置
US9334507B2 (en) 2012-06-15 2016-05-10 Microvi Biotech, Inc. Bioprocesses for making butanol
WO2013188858A2 (en) 2012-06-15 2013-12-19 Microvi Biotech Inc. Novel biocatalyst compositions and processes for use
US9752164B2 (en) 2012-06-15 2017-09-05 Microvi Biotech, Inc. Enhanced efficiency ethanol and sugar conversion processes
US9255281B2 (en) 2012-06-15 2016-02-09 Microvi Biotech Inc. Bioconversion processes using water-insoluble liquids
CN102827310B (zh) * 2012-09-24 2014-08-27 上海交通大学 光化学引发系统及采用其的引发透明体系或不透明体系光聚合或包埋的方法
WO2014081969A1 (en) 2012-11-21 2014-05-30 University Of Louisville Research Foundation, Inc Compositions and methods for reducing oxidative damage
WO2014123665A1 (en) 2013-02-06 2014-08-14 Kci Licensing, Inc. Polymers, preparation and use thereof
US10624865B2 (en) 2013-03-14 2020-04-21 Pathak Holdings Llc Methods, compositions, and devices for drug/live cell microarrays
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
EP2988699B1 (en) 2013-04-24 2020-05-27 Société des Produits Nestlé S.A. Encapsulation device
DK2996709T3 (da) 2013-05-15 2020-06-02 Univ Leland Stanford Junior Modulering af herpan-bindende epidermal vækstfaktoraktivitet til heling af trommehinde
EP2821060B1 (de) 2013-07-01 2016-09-21 PM-International AG Kosmetisches Kühlgel
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
US9392814B2 (en) 2014-06-06 2016-07-19 Nicholas J. Singer Delivery system for drinks
EP3632478B1 (en) 2014-07-14 2022-09-28 University of Utah Research Foundation In situ solidifying solution and methods of making and using thereof
WO2016033295A1 (en) * 2014-08-27 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Multilayer polymeric matrix based medical devices
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016065255A1 (en) * 2014-10-23 2016-04-28 Gopinath Mani Formulations for tailored drug release
CA3014030C (en) 2015-02-09 2023-10-03 Ori Braun Ophthalmic compositions and methods for reducing oxidative damage to an eye lens
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
USD773313S1 (en) 2015-06-23 2016-12-06 Nicholas J. Singer Package
GB201519811D0 (en) * 2015-11-10 2015-12-23 Univ Belfast Ocular compositions
US20170173209A1 (en) * 2015-12-18 2017-06-22 Rousseau Research, Inc. Wound closure compositions and method
WO2017151773A1 (en) 2016-03-01 2017-09-08 Prodo Laboratories, Inc. Encapsulation methods and compositions
IL262802B2 (en) 2016-05-16 2025-04-01 Intarcia Therapeutics Inc Glucagon receptor selective polypeptides and methods of using them
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018089601A1 (en) 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues
AU2016429418B2 (en) 2016-11-10 2023-07-20 Viacyte, Inc. PDX1 pancreatic endoderm cells in cell delivery devices and methods thereof
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
AR111216A1 (es) * 2017-02-23 2019-06-19 Japan Vam & Poval Co Ltd Dispositivo de integración celular o tisular
JP2019083794A (ja) * 2017-11-10 2019-06-06 永嶋　良一 担体の製造方法、および担体
CN108159023A (zh) * 2017-12-22 2018-06-15 杭州高斯博医疗用品有限公司 一种冷敷用水凝胶贴的制备方法及产品
WO2019147922A2 (en) 2018-01-26 2019-08-01 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion
CN108548656B (zh) * 2018-03-29 2021-08-03 昂纳信息技术（深圳）有限公司 一种用于to-can激光器的测试装置和测试系统
WO2021016055A1 (en) * 2019-07-19 2021-01-28 The Secant Group, Llc Poly(glycerol sebacate)-infused hollow lumen composite graft
WO2021048250A1 (en) * 2019-09-10 2021-03-18 Fundació Institut De Bioenginyeria De Catalunya Multi-layered cell capsules and uses thereof
CN110755628B (zh) * 2019-11-13 2023-06-20 华南协同创新研究院 一种乏氧响应性壳聚糖药物载体及其制备方法与应用
CN111318237B (zh) * 2020-03-20 2022-07-05 武汉轻工大学 一种胶原-壳聚糖水凝胶及其制备方法
WO2021207223A1 (en) 2020-04-06 2021-10-14 The Secant Group, Llc Water-mediated polyester (meth)acrylation systems
IL297648A (en) 2020-04-28 2022-12-01 Univ Miami Tailored plating of cells for immunoisolation
CA3200422A1 (en) * 2020-10-28 2022-05-05 Kuraray Co., Ltd. Hydrogel for cell embedding, immunoisolation device, and transplant material
MX2022005428A (es) 2021-05-07 2022-11-08 Abulkalam Mohammed Shamsuddin Metodo, dispositivo y kit para clasificacion de poblacion para cancer, recurrencia de cancer y condiciones precancerosas en individuos sin sintomas.
WO2023133539A1 (en) * 2022-01-06 2023-07-13 Case Western Reserve University Systems and methods of generating lipid, protein, and/or protein shelled bubbles
WO2023164171A2 (en) 2022-02-25 2023-08-31 Viacyte, Inc. Multilayer implantable cell encapsulation devices and methods thereof
CN118416015B (zh) * 2024-07-04 2024-09-06 西部生科生物医学科技(成都)有限公司 一种富含脂肪干细胞外泌体的组合物及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193845A (en) * 1973-11-15 1980-03-18 Japan Atomic Energy Research Institute Immobilization of enzymes or bacterial cells
JPS5126285A (en) * 1974-08-30 1976-03-04 Japan Atomic Energy Res Inst Koso mataha kintaiofukunda soseibutsu no seizohoho
DE2633259C3 (de) * 1975-07-23 1984-11-15 Japan Atomic Energy Research Institute, Tokio/Tokyo Verfahren zum Unbeweglichmachen von Enzymen oder enzymhaltigen Zellen
US4195129A (en) * 1975-11-26 1980-03-25 Kansai Paint Co., Ltd. Method for immobilizing enzymes and microbial cells
JPS5296791A (en) * 1976-02-09 1977-08-13 Japan Atom Energy Res Inst Preparation of composition including enzymes or microorganisms
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
DE2965725D1 (en) * 1978-07-19 1983-07-28 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
FR2433949A1 (fr) * 1978-08-25 1980-03-21 Commissariat Energie Atomique Substrat hydrophobe apte a liberer une substance chimique
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
JPS5911563B2 (ja) * 1980-02-27 1984-03-16 日本原子力研究所 多層構造の徐放性複合体を製造する方法
US4376059A (en) * 1980-04-11 1983-03-08 Exxon Research And Engineering Co. Process for preparing artificial red cells
US4390521A (en) * 1980-04-11 1983-06-28 Exxon Research And Engineering Co. Artificial red cells
FR2485370A1 (fr) * 1980-06-30 1981-12-31 Commissariat Energie Atomique Support inerte en copolymere reticule, son procede de preparation et son utilisation pour la realisation de medicaments retard
SE441009B (sv) * 1982-03-08 1985-09-02 Kjell Nilsson Sett att immobilisera levande biomaterial i perlformiga polymerer
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4605622A (en) * 1983-11-15 1986-08-12 Kansai Paint Co., Ltd. Process for producing granular fixed enzymes or microorganisms
EP0160260A3 (de) * 1984-05-02 1986-10-08 Bayer Ag Verfahren zur Immobilisierung von biologischem Material
JPS6132271A (ja) * 1984-07-24 1986-02-14 Canon Inc 記録装置
DE3617875C2 (de) 1985-06-28 1993-10-14 Hitachi Plant Eng & Constr Co Verfahren zum Immobilisieren von Mikroorganismen
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
JPS6214781A (ja) * 1985-07-15 1987-01-23 Taiyo Kagaku Kk リパ−ゼの固定化方法
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US5037656A (en) * 1986-12-04 1991-08-06 Millipore Corporation Porous membrane having hydrophilic and cell growth promotions surface and process
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
JP2651516B2 (ja) * 1989-12-13 1997-09-10 国立循環器病センター総長 ハイブリッド型人工膵臟
US5104957A (en) * 1990-02-28 1992-04-14 Autogenesis Technologies, Inc. Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
KR930006431B1 (ko) 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5232984A (en) * 1990-10-15 1993-08-03 The Board Of The Regents The University Of Texas Biocompatible microcapsules
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
JP3184555B2 (ja) 1991-05-28 2001-07-09 松下電工株式会社 吸湿器
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1994015589A1 (en) * 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
EP0627911B1 (en) * 1992-02-28 2000-10-25 Board Of Regents The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5578442A (en) * 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP0641196B1 (en) * 1992-05-29 2001-08-22 Vivorx, Incorporated Microencapsulation of cells
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
WO1994012161A1 (en) * 1992-11-24 1994-06-09 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsules

Also Published As

Publication number Publication date
EP0627912A1 (en) 1994-12-14
JPH07506961A (ja) 1995-08-03
US20020058318A1 (en) 2002-05-16
US5801033A (en) 1998-09-01
EP0627912B1 (en) 2004-05-12
DE69333512T2 (de) 2005-05-12
WO1993016687A1 (en) 1993-09-02
DE69333512D1 (de) 2004-06-17
DK0627912T3 (da) 2004-06-28
CA2117584C (en) 1998-09-22
AU3780993A (en) 1993-09-13
US5529914A (en) 1996-06-25
PT627912E (pt) 2004-08-31
NZ251039A (en) 1996-03-26
CA2117584A1 (en) 1993-09-02
US6258870B1 (en) 2001-07-10
US6911227B2 (en) 2005-06-28
JP3011767B2 (ja) 2000-02-21
AU683209B2 (en) 1997-11-06
EP0627912A4 (en) 1995-07-26
ATE266389T1 (de) 2004-05-15
KR100323043B1 (ko) 2002-07-27
ES2220906T3 (es) 2004-12-16
BR9306041A (pt) 1997-11-18

Similar Documents

Publication Publication Date Title
KR950700054A (ko) 생물학적 물질의 코팅 또는 캡슐화 고분자 및 그 방법
US5834274A (en) Gels for encapsulation of biological materials
EP0635040B1 (en) Crosslinked biocompatible encapsulation compositions and methods
US7413781B2 (en) Gels for encapsulation of biological materials
Sawhney et al. Modification of islet of langerhans surfaces with immunoprotective poly (ethylene glycol) coatings via interfacial photopolymerization
US5837747A (en) Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US20080274201A1 (en) Gels for encapsulation of biological materials
US20030087985A1 (en) Gels for encapsulation of biological materials
Quek et al. Photo-crosslinkable microcapsules formed by polyelectrolyte copolymer and modified collagen for rat hepatocyte encapsulation
JP2002538194A (ja) 生体活性物質用細胞保護生体適合封入系及びその製造方法
US20040138329A1 (en) Gels for encapsulation of biological materials
WO1988000237A1 (en) Covalent membranes
WO2004093846A2 (en) Charged initiator polymers and methods of use
EP1613749B1 (en) Ligand-coupled initiator polymers and methods of use
EP0259365A1 (en) Covalent membranes
Hubbell et al. Implantable substrate coated with a macromer having free radical polymerizable substituents

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 19940829

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
E601 Decision to refuse application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980302

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000331

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010420

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20011024

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20020121

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20020122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20050119

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20060119

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20070216

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20080211

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20090423

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20100319

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20110119

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20120109

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20130122

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20130122

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20131022

Termination category: Expiration of duration